First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: A phase II study (SUPAP) by the French Genitourinary Group (GETUG)

Annals of Oncology

Volumn 26, Issue 6, 2015, Pages 1123-1128

  Ravaud, Alain ^a   Oudard, S ^b   De Fromont, M ^c   Chevreau, C ^d   Gravis, G ^e   Zanetta, S ^f   Theodore, C ^g   Jimenez, M ^h   Sevin, E ⁱ   Laguerre, B ^j   Rolland, F ^k   Ouali, M ^d   Culine, S ^l   Escudier, B ^m  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Pathology Department SCP Pathology   (France)

^d INSTITUT CLAUDIUS REGAUD   (France)

^e INSTITUT PAOLI CALMETTES   (France)

^f CENTRE GEORGES FRANÇOIS LECLERC   (France)

^g FOCH HOSPITAL   (France)

^h Research and Development Department   (France)

ⁱ CENTRE FRANÇOIS BACLESSE   (France)

^j CENTRE EUGÈNE MARQUIS   (France)

^k UMR INSERM U892 CNRS 6299   (France)

^l SAINT LOUIS HOSPITAL   (France)

^m INSTITUT GUSTAVE ROUSSY   (France)

more..

Author keywords

Anti angiogenic; Papillary renal cell carcinoma; Renal cell carcinoma; Sunitinib; Type 1 papillary renal cell carcinoma; Type 2 papillary renal cell carcinoma

Indexed keywords

SUNITINIB; ANGIOGENESIS INHIBITOR; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER SURVIVAL; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG SAFETY; FOLLOW UP; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; INTERMEDIATE RISK POPULATION; KIDNEY METASTASIS; LUNG EMBOLISM; MAJOR CLINICAL STUDY; METASTATIC PAPILLARY CELL CARCINOMA; METASTATIC PAPILLARY RENAL CELL CARCINOMA; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; OVERALL SURVIVAL; PAPILLARY CARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; TREATMENT OUTCOME; AGED; CARCINOMA, RENAL CELL; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; FRANCE; KAPLAN MEIER METHOD; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; RISK FACTOR; SECONDARY; TIME FACTOR;

AGED; ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FRANCE; HUMANS; INDOLES; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRROLES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84937640430     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv149     Document Type: Article

References (31)

1. Renshaw AA, Zhang H, Corless CL, Fletcher JA, Pins MR. Solid variants of papillary (chromophil) renal cell carcinoma: clinicopathologic and genetic features. Am J Surg Pathol 1997; 21: 1203-1209.
2. Kovacs G, Füzesi L, Emanual A et al. Cytogenetics of papillary renal cell tumors. Genes Chromosomes Cancer 1991; 3: 249-255.
3. Zbar B, Klausner R, Linehan WM. Studying cancer families to identify kidney cancer genes. Annu Rev Med 2003; 54: 217-233.
4. Amin MB, Tamboli P, Javidan J et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol 2002; 26: 281-291.
5. Pignot G, Elie C, Conquy S et al. Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 subclassification. Urology 2007; 69: 230-235.
6. Mejean A, Hopirtean V, Bazin JP et al. Prognostic factors for the survival of patients with papillary renal cell carcinoma: meaning of histological typing and multifocality. J Urol 2003; 170: 764-767.
7. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124.
8. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-2111.
9. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281.
10. Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28: 1061-1068.
11. Escudier B, Eisen T, Porta C et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25(Suppl 3):iii49-iii56.
12. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology™ Kidney Cancer (Version 3.2015). http://www.nccn.org/index.asp (12 September 2014, date last accessed).
13. Dutcher JP, de Souza P, McDermott D et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histology. Med Oncol 2009; 26: 202-209.
14. Choueiri T, Plantade A, Elson P et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008; 26: 127-131.
15. Gore ME, Szczylik C, Porta C et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009; 10: 757-763.
16. Stadler WM, Figlin RA, McDermott DF et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 2010; 116: 1272-1280.
17. Jacobsen J, Grankvist K, Rasmuson T et al. Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU Int 2004; 93:297-302.
18. Gunningham SP, Currie MJ, Han C et al. Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas:regulation by the von Hippel-Lindau gene and hypoxia. Cancer Res 2001; 61:3206-3211.
19. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
20. Cancer Therapy Evaluation Program: Common Terminology Criteria for Adverse Events (CTCAE) v. 3.0. http://ctep.info.nih.gov/reporting/ctc.html.
21. Motzer RJ, Mazumdar M, Bacik J et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17:2530-2540.
22. Kroeger N, Xie W, Lee JL et al. Metastatic non clear cell renal cell carcinoma (nccRCC) treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium (IMDC) Criteria. Cancer 2013; 1119: 2999-3006.
23. Molina AM, Feldman DR, Ginsberg MS et al. Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma. Invest New Drugs 2012; 30:335-340.
24. Lee JL, Ahn JH, Lim HY et al. Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma. Ann Oncol 2012; 23: 2108-2114.
25. Tannir NM, Plimack E, Ng C et al. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol 2012; 62: 1013-1019.
26. Tannir NM, Jonasch E, Altinmakas E et al. Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (The ESPN Trial): a multicenter randomized phase 2 trial. J Clin Oncol 2014; 32(5s suppl): abstr 4505.
27. Escudier B, Bracarda S, Maroto JP et al. Open-label phase II trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis. Eur J Cancer 2013; 23(Suppl 2): abstr 2706, S643.
28. Koh Y, Lim HY, Ahn JH et al. Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma. Ann Oncol 2013; 24: 1026-1031.
29. Voss MH, Bastos DA, Karlo CA et al. Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoïd histologies. Ann Oncol 2014; 25: 663-668.
30. Motzer RJ, Barrios CH, Kim TM et al. RECORD-3: phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus firstline sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol 2013; 31: abstr 5404.
31. Choueiri TK, Vaishampayan U, Rosenberg JE et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol 2013; 31: 181-186.